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Summary: Osteogenic protein-1 (OP-l/BMP-7), a member of the transforming growth factor (TGF-ß) superfamily
of proteins, is shown to be expressed at sites of epithelial-mesenchymal tissue interaction during human fetal
development. In the present study, we examined the expression of OP-1 in human placentas (5-11 weeks of
gestation and full term) using in situ hybridization and immunohistochemistry methods. The results show that OP-
1 was expressed in cytotrophoblasts (Langhans9 layer) of the chorionic villi in early and full term placentas.
Employing highly purified cytotrophoblast cultures which fused to form functional syncytiotrophoblasts, we showed
that exogenously added recombinant OP-1, in the presence of low serum concentration, reduced the secretion of
chorionic gonadotropin and progesterone by 60% and 36%, respectively, compared with control cultures. The results
suggest that osteogenic protein-1 is synthesized locally by cytotrophoblasts and may be involved in the regulation
of human pregnancy by controlling reproductive hormonal secretion.
Introduction
Transforming growth factor-beta (TGF-ß) is a superfam-
ily of signalling proteins expressed temporally and spa-
tially at specific sites of morphogenetic events during
development. These proteins have been identified in var-
ious developmental systems, in both invertebrates and
vertebrates. They include the activins and inhibins, os-
teogenic bone morphogenetic proteins OP-1 to OP-3 (2,
3), BMP-2 to BMP-6 (4, 5), mesoderm inducing factor
from Xenopus laevis egg (Vg-1) (6), Muellerian inhibit-
ing substance (MIS) (7), mammalian protein related to
Xenopus Vg-1 (BMP-6) (8), growth/differentiation
factors (GDF-1, GDF-3, GDF-9) (9, 10) and cartilage
derived morphogenetic proteins (CDMP-1 and CDMP-
2 or GDF-5 and 6) (11, 12). The decapentaplegic (DPP)
and 60A proteins, which are involved in Drosophila
pattern formations, are homologues of bone morphogen-
etic proteins (13, 14).
The proteins of the TGF-ß superfamily are produced as
a precursor that is three times larger than mature protein;
the precursor is then processed at proteolytic cleavage
sites conforming to the sequence RXXR (3). The C-ter-
minal mature proteins are composed of disulphide-
linked dimers with striking identity in the conserved
seven cysteine motifs (15). Despite the similar structural
features, the temporal and spatial expression of these
proteins suggest a functional specificity among them
(16-20). Osteogenic protein-1 (OP-l/BMP-7) induces
new bone formation in vivo and plays a significant role
in cartilage and bone metabolism (21—26).
The presence of high levels of osteogenic protein-1 mes-
sage in the kidney (19, 27) suggests that OP-1 may have
a role in the development of kidney. In addition, the
presence of OP-1 in the uterus (28) and a steep decline
of OP-1 expression at the onset of pregnancy suggest
that reproductive hormones may influence and regulate
osteogenic protein-1 expression locally in uterus (28).
In the present study, we examined the distribution of
osteogenic protein-1 in human placentas during preg-
nancy, and examined the effect of OP-1 on the regula-
tion of hormones associated with pregnancy using hu-
man trophoblast cultures. The results show that osteoge-
nic protein-1 is expressed and plays a role in regulation
of the hormonal secretion during pregnancy.
Materials and Methods
Human tissues
Whole human embryos (gcstational age 5—14 weeks) obtained
from legal abortions at the University of Zagreb Medical School
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were used in this study. The gestational age of each fetus was
estimated on the basis of crown-rump length and pregnancy
records of the conceptual age. The material was fixed at 4 °C
in paraformaldehyde (40 g/1) in 0.1 mol/1 phosphate buffer (pH
7.2), embedded in paraffin and cut serially at 5 μηι. The pro-
cedure for the human autopsy material was approved and con-
trolled by the Internal Review Board of the Ethical Committee
at the School of Medicine, the University of Zagreb, and the
Office of Human Subjects Research (OHSR) at the National
Institutes of Health, Bethesda, MD. The same collection has
already been used for localizing bone morphogenetic protein-3
(BMP-3) and OP-1 in skeleton and abdominal organs during
human development (17-19).
Mouse tissue
Postimplantation embryos were obtained from outbred females
mated with Fl males. At midday the vaginal plug was considered
to be 0.5 days p. c. Tissues were fixed at 4 °C in 4% paraformalde-
hyde in phosphate-buffered saline, and embedded in paraffin. Serial
sections were mounted on silanated glass slides, incubated over-
night at 40-45 °C and stored at 4 °C until use.
Probe construction
For the detection of mouse OP-1, a 679 base pair BstXl-BgR-frag-
ment (pO 319-3) covering amino acids 63-263 of the pro-region
and the first 25 amino acids of the N-terminal part of the mature
polypeptide was used (27). The long fragment was subcloned into
a pBluescript II (SK)"1"-vector, from which the Kpnl-C\a and Spel-
Sacl multiple cloning site (MCS) fragments were eliminated to pre-
vent cross-hybridization with ribosomal RNA sequences. Based on
the comparison of OP-1 probes with other bone morphogenetic
proteins, the identity did not exceed 29% [BMP-2 (27%), BMP-3
(28%), BMP-4 (26%), BMP-5 (24%), BMP-6 (29%)], both before
and after alkaline hydrolysis, making cross-reactivity unlikely
(GeneWorks 2.2.1, IntelliGenetics™, CA). Single-strained sense
and anti-sense RNA probes were labelled with [a-35S]UTP (New
England Nuclear, Boston, MA) by in vitro-transcription using
either SP6 or T7 polymerase.
In situ hybridizat ion
For in situ hybridization, sections were cut at 5-7 μπι thickness,
mounted on silanated slides, heated at 45 °C overnight, and kept
at 4 °C. They were then deparaffinized, rehydrated, postfixed for
20 min in 4% paraformaldehyde and processed as previously
described (17, 19). Briefly, pre-treatment included incubation in
0.2 moVl HC1 (5 min), proteinase K-digestion (20 g/1; 10 min),
additional postfixation (5 min), blocking of non-specific sulphur-
binding sites with iodoacetamide (0.37 g/400 ml; 925 mg/1) and
N-ethylmaleimide (0.25 g/400 ml; 625 mg/1), acetic anhydride
treatment (5 g/1 in 0.1 mol/1 triethanolamine-HCl, pH 8.0; 2 X 10
min), and dehydration using a graded series of ethanol. Sections
were hybridized under siliconized coverslips for 16-18 h at
50 °C in a humid chamber in hybridization buffer (50% form-
amide, 10% dextran sulphate, saline/sodium citrate (0.60 mol/1
NaCl, 0.060 mol/1 Na-citrate, pH7), 10 mmol/1 dithiothreitol,
Denhardts solution (200 mg/1 bovine serum albumin, 200 mg/1
Ficoll, 200 mg/1 polyvinylpyrrolidone); 500 mg/1 each of salmon
sperm DNA and yeast tRNA, and 0.2-0.4 mg/1 35S-labelled
asymmetric RNA probes. After hybridization the sections were
washed essentially as described earlier (17), including the
following steps: 15 min in saline/sodium citrate (0.30 mol/1
NaCl, 0.030 mol/1 Na-citrate), 50 °C; 20 min in 50% formamide
Na-citrate (0.30 mol/1 NaCl, 0.030 mol/1 Na-citrate, 20 mmol/1
dithiothreitol), 65 °C; 2 X 10 min in Tris/EDTA/NaCl buffer (10
mmol/1 Tris-HCl, pH 7.5; 5 mmol/1 EDTA, 0.5 mol/1 NaCl),
37 °C; 30 min in Tris/EDTA/NaCl buffer containing 20 mg/1
RNase A, 37 °C; 10 min in Tris/EDTA/NaCl buffer, 37 °C;
2 X 15 min in saline/sodium citrate (0.30 mol/1 NaCl, 0.030
mol/1 Na-citrate), 65 °C; and finally to 15 min washes in saline/
sodium (0.15 mol/1 NaCl, 0.015 mol/1 Na-citrate), 65 °C. Sec-
tions were then dehydrated through an upgraded series of ethanol
containing 0.3 mol/1 ammonium acetate, covered with NTB-2
emulsion (Kodak), and exposed between 1 and 3 weeks. After
development, the slides were stained with 1 g/1 toluidine blue,
dehydrated, cleaned with xylene and mounted with Permount.
OP-1 antibodies production
Several polyclonal and monoclonal antibodies that recognize speci-
fically the mature osteogenic protein-1 molecule have been pro-
duced and characterized (19). Briefly, the polyclonal rLOP anti-
body was generated in rabbits using the mature domain of osteoge-
nic protein-1 subunit (amino acids 293-431) (2) expressed in
Escherichia coli as immunogen. The polyclonal SER-17 antibody
was generated in rabbits using a synthetic peptide of 17 amino
acids representing the N-terminus of mature osteogenic protein-1
monomer (amino acids 293-309) (2). Two monoclonal antibodies,
1BJ2-D3 and J2G3, capable of neutralizing osteogenic protein-1
activity were also used for immunohistochemieal staining.
Preparation of dispersed mononuclear trophoblasts
Normal placentas (8—12 weeks gestation) were obtained immedi-
ately after therapeutic procedures and processed according to the
modified method of Kliman et al. (29). The tissue was rinsed in
sodium chloride (9 g/1) containing bacitracin (Serva, Heidelberg,
Germany; 4 mg/1) and leupeptin (Boehringer, Mannheim, Ger-
many; 3 mg/1). The specimens were then dissected free of connec-
tive tissue and blood vessels, coarsely minced and transferred to
20 ml pre-warmed calcium-magnesium free Hanks9 solution (CMF
Hanks'; Sigma Diagnostics, St. Louis, USA), containing 25 rnmol/l
HEPES (Sigma), 0.75 g/1 trypsin (Sigma; 1070 U/mg) and 0.6 g/1
DNase I (Sigma; 530 Kunitz units/mg), pH 7.4, and finally incu-
bated in a shaking water bath at 37 °C for 20 min. Tissue fragments
were allowed to settle for l min. Supernatant (15 ml) was removed,
recovered in medium containing fetal calf serum (Gibco, Gaithers-
burg, USA) and centrifiiged at 300 g for 5 min at room temper-
ature. The resultant pellet was resuspended in 5 ml o>MEM
(Sigma) containing 25 mmol/1 HEPES, fetal calf serum, volume
fraction 0.1, and 25 mmol/1 glucose and stored at 4 °C. The remain-
ing placental tissue was digested four more times with the addition
of 20 ml pre-warmed trypsin-DNase solution. Five resultant cell
suspensions were pooled, centrifuged at 300 g for 5 min, and resus-
pended in 3 ml a-MEM-HEPES-glucose.
Culture of trophoblasts
The suspension of isolated cells was layered over a preformed
Percoll gradient made up in Hanks' solution. The gradient con-
sisted of 70% to 20% Percoll (vol/vol) in 10% steps of 3 ml
each, by dilutions of 90% Percoll [9 parts Percoll (Pharmacia,
Uppsala, Sweden): 1 part 10 times concentrated Hanks'] with
calcium-magnesium free Hanks' and layered in a 25 ml conical
polystyrene centrifuge tube. The gradient was then centrifuged
at 400 g at room temperature for 20 min and three regions were
identified, namely:
(1) red blood cells and occasional polymorphonuclear leukocytes
at the bottom,
(2) connective tisssue elements, small vessels and villous frag-
ments at the top, and
(3) mononuclear cells in the middle.
The middle layer was removed, washed once with a-MEM-
HEPES-glucose, resuspended and diluted to a concentration of
3 X 108 cells per litre with α-MEM containing giutamine (Flow,
Bucks, England; 292.3 g/1), penicillin and streptomycin (Sigma;
100000 U/l, 0.1 g/1), and fetal calf serum, volume fraction 0.15.
The cells were plated into 96-well plates (Flow; 200 ml, 60000
cells/well) incubated in a humidified atmosphere with 5% CO2-
95% air at 37 °C for 24 hours. The culture medium was then sup-
plemented with 1 g/1 bovine serum albumin and 1% ITS + TM
premix [Collaborative Research Inc., Bedford, USA; containing in-
sulin (6.25 g/1), transferrin (6.25 g/1), selenious acid (6.25 g/1), bo-
vine serum albumin (1.25 g/1), linoleic acid (5.35 g/I)], osteogenie
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Fig. 1 OP-1 expression in the murine pregnant uterus by in situ hybridization.
Hybridization was done with a 679 base pair BstX\-Bgll OP-1 specific riboprobe.
(A) Transverse toluidine-blue stained brightfield section of a 7-day
pregnant uterus. Arrows indicate layers of giant cytotrophoblast
adjacent to matemal placenta. The developing embryo is in the
middle of the section. Magnification: X 60
(B) Darkfield image of an adjacent section with transcripts local-
ized in the cytotrophoblasts of the placenta (arrows). Magnifica-
tion: X 60
(C) Toluidine-blue stained section of uterus containing the fetus of
a 10-day pregnant mouse. Arrows indicate trophoblastic giant cells.
Magnification: X 60
(D) An adjacent darkfield section with a strong signal in the tro-
phoblastic giant cells (arrows). Bar in (d) indicates 100 μπι in
(a-d). Magnification: X60
protein-1 [Creative BioMolecules, Hopkinton, MA, USA (20
mg/1)] and bone morphogenetic protein-2 [Creative BioMolecules,
Hopkinton, MA, USA, (20 mg/1)]. At designed times, culture media
were removed, frozen at -70 °C and replaced with fresh medium.
Cells were cultured for up to 5 days. Experiments following each
isolation of trophoblasts were done in triplicate, with 12 wells
per group.
Immunos ta in ing methods
Sections were deparaffmized and then treated with 1000 U/l
chondroitinase ABC (Sigma Diagnostics, St. Louis, USA) for 10
min at 37 °C to facilitate the antibody penetration into the tis-
sues. This was followed by exposing the sections to 1 :30
dilution of normal goat serum (Amersham, Buckinghamshire,
England) for 30 min. Sections were then incubated with a dilu-
tion of the primary antibody in TRIS-buffered saline (15 mg/1
protein), 5 g/1 bovine serum albumin (Sigma), overnight at 4 °C.
After washing in TRIS-buffered saline containing 1 g/1 bovine
serum albumin, sections were incubated for one hour with an
affinity-purified secondary antibody, linked to colloidal gold par-
ticles of about 5 run mean diameter (Auroprobe LM; Janssen,
Olsen, Belgium). For control experiments, the primary antibody
was replaced with either
(a) bovine serum albumin,
(b) normal rabbit serum,
(c) IgG preabsorbed with osteogenic protein-1,
(d) secondary antibody alone or
(e) by using the antigen-depleted IgG preparations.
Hormone quantification
For the determination of hormone production by cultured tropho-
blasts conditioned media were collected and stored at -70 °C until
analysed. Oestradiol was determined by a radioimmunoassay, pro-
gesterone was measured using an enzyme immunoassay, and the
-subunit of human chorionic gonadotropin by immunoenzymetric
assay with magnetic solid phase (Serono diagnostics, Coinsins,
Switzerland).
Statistics
All results are expressed as mean ± SEM. Data (12 wells per ex-
perimental group) were tested by Student's t-test, followed by two-
way analysis of variance (ANOVA). Means were then tested by
the ScA^-post-hoc test. Studenfs t-test, ANOVA and Scheffe-
post-hoc tests were performed with the "Crunch" statistical pack-
age.
B
Fig. 2 Specificity of osteogenic protein-1 staining.
(A) Parasagittal section through the placenta of a 22 mm embryo.
The rLOP antibody to osteogenic protein-1 causes intense staining
of the chorionic cell layer (arrows). Magnification: X 25
(B) An equivalent aliquot of antibody preincubated with a solution
to which osteogenic protein-1 had been added gave no staining
(arrows). The dilution of the anti-osteogenic protein-1 IgG prepara-
tion was 1 : 150. Immunogold staining with light green counter-
stain. Bar indicates 20 μπι. Magnification: X 25
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Results
Osteogenic protein-1 expression in murine
trophoblasts
At 7 to 10 days of murine pregnancy, the OP-lmRNA
expression was observed mainly in trophoblastic giant
cells of the fetal placenta (fig. la-d) and remained in
cytotrophoblasts during subsequent development (data
not shown). There were no detectable OP-1 transcripts
in endometrium constituting the maternal placenta. Lo-
calization of OP-1 in fetal tissues is in accordance with
our previous observations (17, 19).
Localization of osteogenic protein-1 in
human placenta during pregnancy
Specificity of immunostaining was initially tested by
using the polyclonal rLOP antibody raised against ma-
ture OP-1 monomer and then by employing the poly-
clonal SER-17 (raised against N-terminal peptide of ma-
ture OP-1) and monoclonal 1B12-D3 antibodies (raised
against mature OP-1 dimer) (18). The specificity of
immunostaining to osteogenic protein-1, was demon-
strated by preincubating the anti-osteogenic protein-1
IgG fractions with a solution of 5 mg/1 of recombinant
human osteogenic protein-1 before use. This procedure
resulted in a complete loss of staining, thus demonstrat-
ing that the osteogenic protein-1 immunoreactivity is
specific (fig. 2a,b). Since the placenta continuously un-
dergoes changes in size, shape and internal structure
during gestation, osteogenic protein-1 distribution was
examined in placentas from 2, 3, 6, 13, 27 and 33 mm
embryos, as well as in full term placentas. Intensive cy-
toplasmic staining was observed in the chorionic cell
layers by the polyclonal rLOP antibody (fig. 3a,b). Os-
teogenic protein-1 was detected in the cytotrophoblast
layer (Langhans' layer) (fig. 3d) of chorionic villi,
which reach the peak of their deVfelopment during the
second month and regress from the 13th week onwards.
Hofbauer cells (fig. 3d), which appear to be phagocytic
and are commonly believed to act as a primitive type of
macrophage, also stained for osteogenic protein-1. In
full term placentas, the remaining cytotrophoblasts still
stained for osteogenic protein-1. These findings suggest
a role for osteogenic protein-1 in early enbryogenesis
and remodelling of the placenta.
Osteogenic protein-1 inhibits hormonal
secretion of cultured human trophoblasts
Highly purified functional cytotrophoblasts were pre-
pared from early and full-term human placentas. The
lack of immunogold staining with antibodies against vi-
mentin, von Willebrand-faclor VIII and ctj-antichymo-
trypsin confirmed Kliman's data (29) that endothelial
cells, fibroblasts, or macrophages did not contaminate
the purified cytotrophoblast preparations. Figure 4
shows isolated human cytotrophoblasts in culture and
formation of human chorionic gonadotropin-positive
syncytia over a period of 18—66 hours. Hormonal secre-
tion was detected 24 hours after culturing the cells,
which correlated with the beginning of cell aggregation.
Isolated human trophoblasts showed a steadily increas-
ing synthesis of human chorionic gonadotropin and pro-
£
Fig. 3 Localization of osteogenic protein-1 in early human placenta.
(A) A chorionic cell layer of a 27 mm embryo stains intensely for
osteogenic protein-1 with rLOP antibody. Magnification: X 5
(B) Higher magnification of (a). Magnification: X 25
(C) Chorionic villi from the placenta of a 13 mm embryo. Osteoge-
nic protein-1 is detectable in the cytotrophoblast cell layer (ar-
rows.). Magnification: X 25
(D) Staining of full term placental tissues with a monoclonal 1B12-
D3 antibody. Remaining cytotrophoblasts continue to show the
presence of osteogenic protein-1 (arrows). Immunogold staining
with light green counterstain. Magnification: X 25.
Bar indicates 100 μπι in (A), 20 μηι in (B, C, D).
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gesterone, reaching maximal values by 96 hours in the
presence of fetal calf serum, volume fraction 0.15 (fig.
5a, b). To test the possible effect of osteogenic protein-
1 on hormonal activity of isolated trophoblast cells, dif-
ferent amounts (1-100 mg/1) of osteogenic protein-1
were added to cultured cells 24 hours after plating. Both
chorionic gonadotropin (fig. 5a) and progesterone (fig.
5b) secretion into the conditioned media were decreased
by 60% and 36% at 72 hours, respectively. The inhibi-
tion was maximal in the presence of 20 mg/1 osteogenic
protein-1 and most effective in the presence of 5 ml/1 of
fetal calf serum. At a high serum content (150 ml/1) in
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Fig. 4 Human trophoblasts in culture.
Highly purified functional cytotrophoblasts were isolated from
early human placentas and grown in α-MEM containing glutamine
and 150 ml/1 fetal calf serum for up to 5 days as described in
Material and Methods. Cells were seeded at 300 xl06/l in 96-well
plates (60 000/well). Cell aggregates formed as early as 24 hours
after plating; these eventually fused to form functional syncytiotro-
phoblasts 24—48 hours after plating. Bar indicates 500 μηι in
(18 h), 380 μιη in (24 h), 250 μπι in (48 h) and 100 μπι in (66 h).
Magnification: X 12 (18 h), X 32 (24 h, 48 h), X 50 (66 h)
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Fig. 5 Hormonal secretion by human trophoblasts treated with a
single dose of osteogenic? protein-1. Cells were cultured in α-MEM
containing glutamine and 5 ml/1 fetal calf serum for up to five days
in 96-well plate (60 000/well), with the addition of osteogenic pro-
tein-1 or bone morphogenetic protein-2 as indicated. Addition of a
single dose of 20kmg/l osteogenic protein-1 24 hours after plating
the cells reduced the secretion of
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(a) chorionic gonadolropin in trophoblast conditioned media by
60%,
(b) progesterone secretion by 36%.
Bone morphogenetic protein-2 (recombinant human BMP-2, 20
mg/1) had no effect on hormone secretion. Experiments were done
in triplicate, with 12 wells per group (n = 12).
* P < 0.01 vs control.
-O- control -*- rhOP-1 -B- rhBMP-2
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the presence of various amounts of osteogenic protein-
1, the differences were less pronounced (data not
shown). The most effective reduction in the secretion of
chorionic gonadotropin at low fetal calf serum concen-
tration was achieved by the addition of 20 mg/1 of os-
teogenic protein-1 immediately after plating (fig. 6).
Low chorionic gonadotropin values were maintained
throughout the experiment by the daily addition of os-
teogenic protein-1.
Discussion
The present study identifies cytotrophoblasts in the hu-
man fetal placenta as a site of OP-1 synthesis during
pregnancy. Moreover, OP-1 seems to be involved in the
regulation of secretion of chorionic gonadotropin and
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Fig. 6 Hormonal secretion by human trophoblasts treated daily
with osteogenic protein-1. Cells were cultured in α-MEM contain-
ing glutamine and 5 ml/1 fetal calf serum for up to five days in a
96-well plate (60 000/well), with the addition of osteogenic pro-
tein-1 or bone morphogenetic protein-2 as indicated. Administra-
tion of osteogenic protein-1 (20 mg/1) immediately after plating,
caused a pronounced decrease in chorionic gonadotropin secretion
by human trophoblasts within 24 hours. In parallel, bone morpho-
genetic protein-2 (recombinant human BMP-2, 20 mg/1) had no
effect on hormone secretion. Experiments following each isolation
of trophoblasts were done in triplicate, with 12 wells per group
(n = 12).
* P < 0.01 vs control.
-D- control -*- rhOP-1 -a- rhBMP-2
progesterone by cytotrophoblasts. During pregnancy
both placental cytotrophoblasts and the developing
embryo synthesize OP-1. Expression of OP-1 appears to
correlate with the biochemical changes associated with
trophoblasts, as evidenced by the secretion of increased
amounts of chorionic gonadotroplri and its peak values
during the first trimester of pregnancy. The specific ac-
tivity of OP-1 on placental hormone secretion was fur-
ther corroborated by the failure of morphogenetic pro-
tein-2 to inhibit, the same assay system. Analysis of the
spatial and temporal expression of OP-1 patterns during
development showed a widespread distribution of OP-1
expression at the sites of specific developmental events
involving epithelial mesenchymal interaction (20). The
detection of OP-1 message in tissues like the kidney,
heart, early limb buds, whisker follicles and teeth, indi-
cates that OP-1 may have, apart from bone induction,
important signalling or regulatory roles during epithe-
lial-mesenchymal interactions. This has been previously
suggested for other members of the TGF- superfamily
(17). Although both OP-1 and BMP-2 induce new bone
and cartilage formation at ectopic sites and share type I
and II, two cell surface receptors, their specific func-
tional roles during development are yet to be discovered.
This system provides a good basis for delineating the
apparent functional differences among the bone morpho-
genetic protein family members.
Since pregnancy and/or the administration of oestrogen
regulates the expression of osteogenic protein-1 in the
uterus, cytotrophoblasts and fetal organs, it is possible
that the osteogenic protein-1 gene may have tissue-spe-
cific regulatory elements in the upstream 5' characteriza-
tion of promotor region. Upstream regulatory sequences
in the osteogenic protein-1 genomic locus, with specific
binding sequences for transcriptional regulatory protein
would provide a better understanding of the temporal
and spatial regulation of OP-1 during tissue morphogen-
esis. Recent studies on deletion of the OP-1 gene suggest
that mice carrying the null mutation died due to lack of a
functional kidney, as well as displaying several skeletal
abnormalities and dysfunction of the fetal placenta, re-
sulting in a small, underdeveloped animal (Karsenty et
al., in preparation). These observations further support
our conclusion that OP-1 has a regulatory role in the
placental cytotrophoblasts during pregnancy.
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